Clinical isolates of Klebsiella pneumoniae and Klebsiella oxytoca collected from 20 Japanese medical facilities between 2000 and 2010 were analysed to evaluate the mechanisms of resistance and antibacterial susceptibilities to 14 antimicrobials. Overall, eight of 484 (1.6 %) K. pneumoniae and 19 of 359 (5.3 %) K. oxytoca were determined to be extendedspectrum b-lactamase (ESBL) phenotype isolates, and the identified ESBLs amongst the K. pneumoniae isolates were CTX-M-2, -3, -14 and -15, and SHV-12. In contrast, overproduction of chromosomal b-lactamase OXY-2, which was due to a distinct mutation at the 210 promoter region of this gene, conferred the ESBL phenotype to all the K. oxytoca isolates except one. Based on the Clinical and Laboratory Standards Institute breakpoints, all the ESBL phenotype K. pneumoniae were susceptible to doripenem, flomoxef, moxalactam (latamoxef), cefmetazole and tazobactam/piperacillin, whereas the ESBL phenotype K. oxytoca were susceptible to ceftazidime and ceftibuten in addition to the above, with the exception of tazobactam/piperacillin. Amongst the oral antimicrobials, ceftibuten was relatively effective against both ESBL phenotype Klebsiella species compared with levofloxacin and amoxicillin/ clavulanic acid.
INTRODUCTION
Antimicrobial resistance due to rapid spread of extendedspectrum b-lactamases (ESBLs) in Enterobacteriaceae is an emerging problem worldwide. The ESBLs confer resistance to various classes of b-lactam such as oxyimino-cephalosporin (e.g. cefotaxime, ceftriaxone and ceftazidime) and monobactam (e.g. aztreonam). Moreover, ESBL-producing Enterobacteriaceae have a tendency toward cross-resistance to non-b-lactam classes of antimicrobials such as quinolone and aminoglycoside agents (Pitout, 2010; Livermore, 2012) .
The currently dominant ESBLs belonging to class A in the Ambler classification are TEM, SHV and CTX-M types. Although the dominant types of ESBLs in the 1990s were SHV and TEM, the rapid spread of CTX-Ms (especially CTX-M-1, -2, -3, -14 and -15) has also been observed in Escherichia coli as well as Klebsiella pneumoniae since the early 2000s (Pitout, 2010; Livermore, 2012) . In Klebsiella oxytoca, the species-specific chromosome-encoded class A b-lactamases called OXY (mainly divided into OXY-1 and -2) are also associated with b-lactam resistance (Fournier et al., 1996) . These enzymes are constitutively produced at low levels, which are sufficient to confer resistance to penicillins but no significant resistance to other b-lactam classes (Livermore, 1995) . However, overproduction of OXYs due to distinct point mutations in the 235 and/or 210 promoter regions of the gene results in additional resistance to aztreonam, combinations of penicillins with b-lactamase inhibitors and oxyimino-cephalosporins,with the exception of ceftazidime (Fournier et al., 1996) .
Several epidemiology studies on ESBL-producing K. pneumoniae in Japan have been reported (Nakamura et al., 2012; Chong et al., 2013) , but little is known (especially in K. oxytoca) about the epidemiology and molecular characteristics of ESBLs. The aim of this study was to investigate the resistance mechanisms to b-lactams amongst ESBL phenotype K. pneumoniae and K. oxytoca isolated in Japan through the 2000s, including antimicrobial susceptibility to parenteral and oral antimicrobials. ) (CLSI, 2013) . The ESBL phenotype isolates used in this study were screened from 484 K. pneumoniae (*80 isolates per year) and 359 K. oxytoca (*60 isolates per year) that were randomly collected from 20 medical facilities in Japan every 2 years between 2000 and 2010. These were mainly isolated from urine and sputum for K. pneumoniae, and urine, pus and blood for K. oxytoca.
Detection of ESBL genes. All isolates positive in ESBL phenotype screening tests were subjected to conventional PCR analysis for the detection of b-lactamase genes. DNA templates were prepared by suspending a freshly grown colony in distilled water, heating at 94 uC for 10 min and then centrifuging to collect supernatant. The PCR amplification with Ex Taq (TaKaRa Bio) consisted of a pre-PCR stage at 94 uC for 5 min, and then 25 cycles at 94 uC for 30 s, at 55 uC for 30 s and at 74 for 1 min, and a final extension stage at 74 uC for 7 min using a C1000 Thermal Cycler (Bio-Rad). Direct sequencing of amplified PCR products including b-lactamase genes and partly their promoter region was performed by Eurofins Genomics. The eight sets of primers used for amplification and sequencing are shown in Table 1 .
Susceptibility testing. MICs were determined by the broth microdilution method with cation-adjusted Mueller-Hinton broth (Becton Dickinson) according to the recommendations of the CLSI (CLSI, 2012) . The following antimicrobials were used: cefotaxime, ceftriaxone, ampicillin, clavulanic acid, sulbactam and tazobactam (US Pharmacopeia); doripenem, moxalactam (latamoxef), flomoxef, ceftibuten and sulfamethoxazole (Shionogi); ceftazidime and cefepime (Chem-Impex International); piperacillin and levofloxacin (LKT Laboratories); amoxicillin (Wako Pure Chemical Industries); cefmetazole (Sigma-Aldrich); and trimethoprim (Nacalai Tesque). MIC interpretation of susceptibility was determined based on the CLSI breakpoint (as the MIC breakpoint of flomoxef was unavailable, that of moxalactam was applied instead) (CLSI, 2013) .
RESULTS

Identification and molecular characterization of ESBL phenotype isolates
Of 484 isolates of K. pneumoniae collected between 2000 and 2010, eight (1.6%) were identified as ESBL phenotype 
*Square brackets present the nucleoside sequence of the 210 promoter region of OXY b-lactamase; the common sequence is GATAGT and the mutation is in italic. .
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T. Sato and others strains ( Table 2 ). The positive rates after 2006 ranged from 2.4 to 3.7% each year. The b-lactamase genes in these eight isolates were sequenced. Almost all of the ESBLs were the CTX-M type; bla CTX-M-2 was identified in all three strains isolated before 2006, and bla CTX-M-3 , bla CTX-M-14 , bla CTX-M-15 or bla SHV-12 was identified in the rest of the strains isolated between 2008 and 2010.
For K. oxytoca, ESBL phenotype isolates were present in 19 of the total 359 (5.3%) isolates (Table 2 ). The positive rates (except for 2004) ranged from 3.3 to 12.1% each year. The ESBL genes were not positive for any other bla TEM , bla SHV or bla CTX-M except for one strain carrying bla CTX-M-3 . Focusing on the chromosome-encoded bla OXY and its promoter region between 235 and 210, the bla OXY-2 gene with a single mutation (either GRA of the fifth base or GRT of the first base) in the 210 promoter sequence was identified in all isolates other than the bla CTX-M-3 -carrying strain. This bla CTX-M-3 -carrying strain was positive for bla OXY-1 with a common 210 promoter sequence (GATAGT). Also, no mutation was found in 235 and gap promoter sequences.
Antimicrobial susceptibility of ESBL phenotype isolates
The results of antimicrobial susceptibility of the ESBL phenotype isolates to 10 parenteral and four oral commonly used antimicrobials are shown in Figs. 1 and 2 , respectively. Based on the CLSI breakpoints, all the K. pneumoniae isolates were susceptible to doripenem, moxalactam, flomoxef, cefmetazole and tazobactam/piperacillin, whereas the ESBL phenotype K. oxytoca were susceptible to ceftazidime and ceftibuten in addition to the above. Amongst the oral antimicrobials tested, ceftibuten showed potent in vitro activity against both ESBL phenotype Klebsiella species compared with levofloxacin and amoxicillin/clavulanic acid. The three K. pneumoniae isolates less susceptible to both ceftazidime and ceftibuten were the strains producing either CTX-M-15 or SHV-12, which were cross-resistant to sulfamethoxazole/trimethoprim. All the K. oxytoca isolates with a mutated promoter of OXY-2 showed high-level resistance to tazobactam/piperacillin as well as other b-lactam/b-lactamase inhibitor combinations, consisting of either sulbactam or clavulanic acid.
DISCUSSION
The recent long-term epidemiology study by Chong et al. (2013) reported that the ESBL-positive rate amongst K. pneumoniae in Japan ranged from 0 to 9.2% between 2003 and 2011. Nakamura et al. (2012) also demonstrated that the rates of ESBL-positive K. pneumoniae in the Kinki region of Japan were from 0 to 2.4% between 2000 and 2009. Similar results were observed in this study, i.e. the detection rate of ESBL phenotype isolates was 1.6% in total through the observation period. These data indicate that the prevalence of ESBL-producing K. pneumoniae is still low compared with those rates in surrounding countries, because recent worldwide surveillance shows global ESBL-positive rates were 20.1% for K. pneumoniae, with the rate in the Asia/Pacific region being relatively high compared with other areas (Hawkey, 2008; Lob et al., 2013) . The two previous studies did not determine the detailed subtypes of CTX-Ms, but our molecular genotyping revealed a subtype in ESBL phenotype K. pneumoniae, i.e. we found the appearance of CTX-M-15, known as the world pandemic ESBL in E. coli. Recently, several researchers have reported acceleration of the increase of the CTX-M-15-producing E. coli ST131 clone in Japan (Nakamura et al., 2012; Yano et al., 2013) . The detection of CTX-M-15-producing K. pneumoniae isolates has also been reported in Asian and Middle East countries, such as South Korea, India and Pakistan (Hawkey, 2008; Livermore, 2012) . This prevalence shift in E. coli is likely to have influenced the appearance of the world pandemic plasmid-mediated CTX-M-15 amongst K. pneumoniae in Japan.
Our study revealed that the ESBL phenotype K. oxytoca isolates in Japan were constantly isolated every year (except for 2004) and the positive rate accounted for 5.3% of all K. oxytoca isolates tested. Although the numbers of isolates in 2008 and 2010 were slightly high, they would be considered insufficient to support the regional outbreaks because these isolates were from seven facilities located up to 1200 km apart. The ESBL-phenotype-positive rate in K. oxytoca was around three times that in ESBL phenotype K. pneumoniae. However, the mechanism conferring ESBL phenotypes is thought to be quite different between K. oxytoca and K. pneumoniae; overproduction of chromosome-encoded b-lactamase (OXY-2) was predominant in K. oxytoca, whereas acquisition of plasmid-mediated ESBLs occurred in K. pneumoniae. Limited in the plasmid-mediated ESBLs, only one strain carrying bla CTX-M-3 was screened amongst K. oxytoca isolates during the observation period. The overproduction of OXY-2 is due to a distinct mutation in the promoter region, which increases the promoter strength by w10-fold (Fournier et al., 1999) . This resistance mechanism of K. oxytoca has been reported since the 1990s (Livermore, 1995; Fournier et al., 1996) . In addition, isolates carrying plasmidmediated ESBLs have been reported in several countries (Zhang et al., 2008; Castanheira et al., 2013) . Our results demonstrate that there was only one strain carrying plasmid-mediated ESBL (CTX-M-3) with a non-mutated OXY promoter region amongst the identified ESBL phenotype isolates, suggesting overproduction of OXY-2 to be the major cause of ESBL phenotypes amongst K. oxytoca isolates in Japan. Intriguingly, in our study, all the isolates harbouring the mutated OXY promoter region were not OXY-1 producers, but OXY-2 producers. The most likely explanation is that substrate catalytic activity between OXY-1 and -2 is somewhat different. We found several isolates of K. oxytoca carrying the bla OXY-1 gene with the mutation conferring an increase of promoter activity that were not judged as the ESBL phenotype by the confirming test using cefotaxime or ceftazidime with clavulanic acid, in spite of lesser susceptibility to tazobactam/piperacillin (MICw64 mg ml
21
) and aztreonam (MIC 4-16 mg ml
). Although overproduction of OXY-1 may confer resistance to limited classes of b-lactams such as penicillins, there is the possibility of the emergence of strains overproducing OXY variants with extended-substrate catalytic profiles by specific amino acid substitutions, as reported previously (Rodríguez-Martínez et al., 2008) . To monitor them, further study focusing on the prevalence of OXY variants and/or mutations conferring overproduction of OXYs that affect antimicrobial susceptibility needs to be continuously addressed. Doripenem (carbapenem) as well as two cephalosporin classes of antimicrobials, moxalactam and flomoxef (oxachephem) and cefmetazole (cephamycin), were thoroughly effective in vitro against these ESBL phenotype K. pneumoniae and K. oxytoca,. We also revealed that ceftibuten (a third-generation cephalosporin) was relatively effective amongst oral antimicrobials against these ESBL phenotype isolates except for CTX-M-15-and SHV-12-producing K. pneumoniae, as in the case of ceftazidime. Twelve of 19 OXY-2-overproducing K. oxytoca were not susceptible to levofloxacin, with a MIC of 4-64 mg ml
. All the b-lactam/b-lactamase inhibitor combinations, including tazobactam/piperacillin, were ineffective against OXY-2-overproducing K. oxytoca, as reported previously (Livermore, 1995; Castanheira et al., 2013) ; thus the spread of these isolates should be carefully monitored and care taken not to be overconfident about the effects of b-lactamase inhibitors.
In summary, this report describes the trends of isolation of ESBL phenotype K. pneumoniae and K. oxytoca between 2000 and 2010 in Japan, and the difference in genes conferring the ESBL phenotype between these two species. Although there are still some active antibacterials left, the further emergence of antibacterial resistance by inappropriate use of antibacterials must be avoided.
